Cite
HARVARD Citation
Gettinger, S. et al. (n.d.). 2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592. Immuno-oncology technology. p. . [Online].